CSF3 and myeloid neoplasm: The debut of low-dose induced remission treatment (low dose of cytarabine and anthracycline in conjunction with granulocyte colony stimulating factor [G-CSF]) was reported in 1995, being applied among aged patients with myeloid tumor and yielding certain efficac y[12].